Chemotherapy and targeted therapy are part of the standard treatments for stage 4 CRC, and various biomarker-guided therapies targeting BRAF mutation and EGFR-mediated signaling have improved patient survival (3). This evidence concerns the gene EGFR and colorectal carcinoma.